Avior Wealth Management LLC Sells 1,304 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Avior Wealth Management LLC trimmed its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 7.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,195 shares of the biotechnology company’s stock after selling 1,304 shares during the quarter. Avior Wealth Management LLC’s holdings in Rocket Pharmaceuticals were worth $191,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Renaissance Technologies LLC bought a new stake in Rocket Pharmaceuticals during the 2nd quarter valued at about $2,144,000. Marshall Wace LLP purchased a new position in shares of Rocket Pharmaceuticals during the second quarter worth approximately $422,000. The Manufacturers Life Insurance Company raised its stake in shares of Rocket Pharmaceuticals by 23.5% during the second quarter. The Manufacturers Life Insurance Company now owns 139,613 shares of the biotechnology company’s stock valued at $3,006,000 after acquiring an additional 26,556 shares in the last quarter. Novo Holdings A S raised its stake in shares of Rocket Pharmaceuticals by 4.8% during the second quarter. Novo Holdings A S now owns 1,100,000 shares of the biotechnology company’s stock valued at $23,683,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Dana Investment Advisors Inc. boosted its holdings in shares of Rocket Pharmaceuticals by 4.4% in the second quarter. Dana Investment Advisors Inc. now owns 13,847 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 586 shares during the period. 98.39% of the stock is owned by hedge funds and other institutional investors.

Rocket Pharmaceuticals Stock Performance

Shares of RCKT opened at $10.71 on Tuesday. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The firm has a market cap of $976.32 million, a PE ratio of -3.89 and a beta of 1.01. Rocket Pharmaceuticals, Inc. has a 12 month low of $10.07 and a 12 month high of $31.47. The stock has a fifty day moving average price of $12.27 and a 200-day moving average price of $16.67.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.07. Equities research analysts predict that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $52.00 target price on shares of Rocket Pharmaceuticals in a report on Tuesday, November 19th. Chardan Capital reaffirmed a “buy” rating and issued a $62.00 price objective on shares of Rocket Pharmaceuticals in a research note on Monday, November 18th. Scotiabank assumed coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $50.00 target price on the stock. Jefferies Financial Group began coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, December 18th. They issued a “buy” rating and a $29.00 price target for the company. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $39.00 price objective on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.27.

Insider Buying and Selling

In related news, CEO Gaurav Shah sold 11,091 shares of the company’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $13.05, for a total value of $144,737.55. Following the transaction, the chief executive officer now directly owns 707,328 shares of the company’s stock, valued at $9,230,630.40. This represents a 1.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 14,386 shares of company stock worth $185,345 in the last three months. Corporate insiders own 28.50% of the company’s stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.